RHOA rs11688000: Genetics and Insomnia Complaints
The genetic variant rs11688000 is a single-nucleotide polymorphism located on chromosome 3 in the vicinity of the RHOA gene. In genome-wide association studies, this locus has been identified in connection with self-reported insomnia complaints, including frequent nocturnal awakenings. However, its overall effect size is very modest and the current clinical evidence linking it directly to clinical sleep disorders remains limited.
What each genotype means
Baseline insomnia complaint likelihood
Carrying two copies of the C allele is associated with baseline rates of self-reported insomnia complaints and nocturnal awakenings in population cohorts. Because the overall evidence linking this genomic region near RHOA to sleep disruption is limited, this genotype is not considered a strong determinant of sleep quality. Overall sleep health continues to depend heavily on lifestyle factors, sleep hygiene, and broader health status.
Carried by approximately 34% of individuals of European ancestry, with varying frequencies across other global populations.
Slightly altered insomnia complaint likelihood
Carrying one copy of the T allele near RHOA has been associated with subtle statistical variations in the likelihood of reporting insomnia complaints or waking up during the night in large genetic studies. Current published research classifies this association as limited, meaning it reflects a minor statistical correlation across populations rather than a direct cause of sleep issues. This genotype does not predict clinical sleep disorders or require medical management.
Carried by roughly 48% of individuals of European ancestry, making it the most frequent genotype at this locus in European populations.
Modestly altered insomnia complaint likelihood
Carrying two copies of the T allele near the RHOA gene is correlated with a minor difference in the odds of reporting frequent nighttime awakenings or insomnia symptoms in population datasets. Evidence supporting a direct functional effect of this locus on sleep architecture remains limited, so any individual contribution to your sleep patterns is small. Daily routines, stress management, and medical factors play a far larger role in overall sleep quality.
Carried by approximately 18% of individuals of European ancestry, with lower observed frequencies in several non-European ancestral groups.
Genomic Location and Variant Characteristics
The single-nucleotide polymorphism rs11688000 is an intergenic or near-gene DNA sequence variation situated on chromosome 3. In the human reference genome, this locus involves a common nucleotide substitution between cytosine (C) and thymine (T). Rather than altering the amino acid sequence of a protein directly, rs11688000 sits in a non-coding regulatory region adjacent to several genes, most notably RHOA. Variants residing in non-coding genomic regions often exert subtle regulatory effects by influencing transcriptional binding, chromatin accessibility, or nearby gene expression across specific tissues, such as the brain. Because it does not cause a direct disruption to a protein-coding sequence, rs11688000 acts primarily as a common tagging marker across large population-scale genetic analyses rather than a severe, monogenic driver of disease.
The Biological Role of RHOA
The closest notable gene to rs11688000 is RHOA, which encodes the ras homolog family member A protein. RHOA is a small GTPase belonging to the Rho family of GTPases, functioning as a critical molecular switch in diverse cellular pathways. It plays central roles in actin cytoskeleton reorganization, cell morphology, cell motility, neuronal development, and the maintenance of synaptic plasticity in the central nervous system. Synaptic modeling and structural plasticity in brain circuits are increasingly recognized as physiological components of sleep homeostasis and the regulation of sleep-wake cycles. While researchers hypothesize that non-coding variants near RHOA might subtly alter neurodevelopmental or signaling pathways linked to neurological arousal, a definitive biological mechanism directly tying rs11688000 to altered RHOA function in human sleep circuits has not yet been experimentally proven.
GWAS Evidence and Association with Insomnia Complaints
Large-scale genome-wide association studies (GWAS) analyzing sleep patterns—particularly datasets derived from the UK Biobank and international sleep consortia—have evaluated rs11688000 in relation to self-reported insomnia traits. In these studies, participants answered questionnaires regarding whether they experienced trouble falling asleep or suffered from frequent awakenings in the middle of the night. Cohort analyses identified rs11688000 near RHOA as a lead locus associated with these insomnia complaints. Despite reaching statistical thresholds in population cohorts, the individual effect size is exceptionally small, slightly shifting statistical probability rather than causing sleep pathology. The overall evidence strength for rs11688000 remains categorized as limited because sleep architecture is profoundly polygenic, shaped by hundreds of loci acting alongside psychosocial and behavioral exposures.
Practical Implications and Scientific Limitations
Possessing a particular genotype at rs11688000 does not mean an individual is destined to develop insomnia, nor does the alternative genotype guarantee restorative sleep. Complex behavioral phenotypes like sleep duration, sleep latency, and middle-of-the-night awakenings arise from an intricate interplay among polygenic risk, circadian biology, mental health, caffeine intake, screen exposure, and ambient environment. Consumers reviewing their raw personal genomic data should view rs11688000 strictly as a scientific research marker rather than a diagnostic indicator. Genotypic results cannot be used to diagnose an official sleep disorder or guide pharmacotherapy. Anyone experiencing chronic sleep problems, daytime exhaustion, or interrupted sleep should consult a licensed healthcare professional to explore clinically validated diagnostic assessments and behavioral therapies.
How common is this variant?
The minor allele (T) frequency is approximately 0.42 in populations of European ancestry, meaning both the heterozygous and homozygous forms are common. Population data in non-European ancestries remain more limited, and frequency distributions vary across diverse continental groups.
Frequently asked questions
Does having the rs11688000 variant mean I have insomnia?
No. The rs11688000 variant is merely a statistical marker identified in large population studies of self-reported sleep complaints. It confers only a minute influence on probability and does not diagnose clinical insomnia or predict nightly sleep quality.
What role does the RHOA gene play in sleep?
RHOA encodes a signaling protein involved in cell structure and synaptic connectivity within the nervous system. While synaptic remodeling is important for the sleep-wake cycle, research has not yet confirmed the exact biological chain of events connecting rs11688000 to sleep regulation.
Can testing rs11688000 help choose sleep medication?
No. There are no clinical guidelines or pharmacogenomic recommendations linking rs11688000 to sleep medication efficacy or dosing. All medication choices and dosing decisions should be evaluated with a qualified physician or pharmacist.
How common is the rs11688000 variant?
The variant is very common, with the minor allele appearing in roughly 42% of chromosomes analyzed in European population cohorts. Because it is widespread, millions of people carry one or two copies without experiencing significant sleep issues.
Sources & further reading
Educational information only, last refreshed 9/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11688000?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29